Danaher unit Cepheid wins approval of point-of-care hepatitis C test

designer491/iStock via Getty Images The U.S. FDA has granted marketing authorization to the Xpert HCV test and GeneXpert Xpress System, the first-ever point-of-care test for hepatitis C, from Danaher ( NYSE: DHR ) subsidiary Cepheid.

The test can be performed in places such as doctors' offices, emergency departments, and urgent care clinics. The test can detect the presence of hepatitis C RNA through a small blood sample from a fingertip in an hour. The agency noted the test allows for a test-and-treat approach where if a patient's results are positive, a treatment plan can be developed potentially during the same visit.

More on Danaher Mar Vista - Danaher: Headwinds Are Primarily Cyclical, Growth To Regain Momentum Danaher Corporation: A Good Medium-Term Bet Value Vs. Growth? Danaher Says Why Not Both? Danaher Corporation (DHR) Presents at BofA Securities 2024 Health Care Conference Call Transcript.